Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia Therapeutics
Astellas is penning a deal with Kelonia Therapeutics to develop in vivo cell therapies to treat cancer, but with a twist.
Not only would the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
